(185 days)
The MeDioStar laser system is intended for surgical, aesthetic applications in the medical specialties of general and plastic surgery and in dermatology.
The MeDioStar laser system is intended for the treatment of benign vascular lesions.
The MeDioStar laser system is intended for the treatment of benign pigmented lesions.
The MeDioStar laser system is intended for hair reduction defined as reduced hair growth with or without maintenance when measured at 6, 9 and 12 months.
The MeDioStar is a pulsed diode laser emitting a wavelength of 750 - 950 nm that is operated with a handpiece in contact with the skin. The system comprises a main console unit, a handpiece and is triggered by means of a footswitch. There are several handpieces, the user can choose from. Moreover, a specific software controls the device functions and allows the user selections through the touchscreen display.
This document is a 510(k) Pre-Market Notification for a medical device, specifically a laser system. It outlines the modifications to an existing device, the MeDioStar, and demonstrates its substantial equivalence to previously cleared predicate devices.
Based on the provided document, there is no information regarding acceptance criteria, reported device performance metrics against those criteria, or clinical study details (sample size, data provenance, expert adjudication, MRMC, standalone algorithm performance, ground truth establishment for test or training sets).
The document explicitly states: "Clinical Performance Data: None".
Therefore, I cannot provide the requested information. The document focuses on demonstrating substantial equivalence through:
- Technical Modifications: Listing specific changes from the predicate device (e.g., GUI design, handpiece port, repetition rate, handpieces, USB drive).
- Comparison of Technical Characteristics: A table comparing the subject device (MeDioStar) to its main predicate (MeDioStar NeXT Family) and two reference predicates (Primelase Excellence, LightSheer Infinity/Duet/Desire) across various parameters like laser source, wavelength, pulse duration, fluence, repetition rate, intended use, and handpiece ports.
- Non-clinical Performance Data: Listing standards to which the device complies (e.g., ISO 60601-1, IEC 62304, ISO 14971) and stating that software verification and validation testing were conducted successfully.
The FDA 510(k) process for this device type often relies on demonstrating substantial equivalence to a legally marketed predicate device rather than requiring new clinical studies and performance benchmarks against specific acceptance criteria. This is particularly true for modifications to existing cleared devices, as is the case here ("Special 510(k)").
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and then the word "ADMINISTRATION" in a smaller font size below the previous line.
October 13, 2020
Asclepion Laser Technologies Gmbh Dania Di Pietro Paolo Executive Director Busseler Str. 10 Jena, Thuringia 07747 Germany
Re: K192483
Trade/Device Name: MeDioStar Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX
Dear Dania Di Pietro Paolo:
The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated March 13, 2020. Specifically, FDA is updating the SE Letter to address the error in the company name as an administrative correction.
Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Purva Pandya, OHT4: Office of Surgical and Infection Control Devices, 240-402-9979, purva.pandya@fda.hhs.gov.
Sincerely.
Purva U. Pandya -S
Purva Pandya Acting Assistant Director OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the symbol of the Department of Health & Human Services on the left and the FDA acronym followed by the full name of the agency, "U.S. Food & Drug Administration," on the right. The FDA part of the logo is in blue, with the acronym in a solid blue square and the agency's name in a lighter shade of blue.
Aslepion Laser Technologies GmbH Dania Di Pietro Paolo Executive Director Busseler Str. 10 Jena, 07747 De
Re: K192483
Trade/Device Name: MeDioStar Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: GEX Dated: February 24, 2020 Received: February 27, 2020
Dear Dania Di Pietro Paolo:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
{2}------------------------------------------------
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE(@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Jessica Mavadia-shukla -S
Jessica Mavadia-Shukla, Ph.D. Acting Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Indications for Use
510(k) Number (if known) K192483
Device Name
MeDioStar
Indications for Use (Describe)
The MeDioStar laser system is intended for surgical, aesthetic applications in the medical specialties of general and plastic surgery and dermatology.
The MeDioStar laser system is intended for the treatment of benign vascular lesions.
The MeDioStar laser system is intended for the treatment of benign pigmented lesions.
The MeDioStar laser system is intended for hair reduction defined as reduced hair growth with or without maintenance when measured at 6, 9 and 12 months.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the logo for Asclepion Laser Technologies. The word "Asclepion" is written in a bold, gray font. Below it, the words "Laser Technologies" are written in a smaller, gray font. To the right of the word "Asclepion" is a cluster of blue circles of varying sizes.
Special 510(k) SUMMARY K192483
MeDioStar
This Special 510(k) summary of safety and effectiveness for the Asclepion Laser Technologies GmbH MeDioStar is submitted in accordance with the requirements of 21 CFR 907.92 and follows Office of Device Evaluation Guidance concerning the organization and content of a 510(k) summary.
| Applicant: | ASCLEPION LASER TECHNOLOGIES GmbHBruesseler Str. 1007747 Jena, Germany |
|---|---|
| Contact Person: | Mrs. Dania Di Pietro Paolo, Ph.DRegulatory Affairs Manager |
| Phone:Fax:E-mail: | +49 3641 77 00 213+49 3641 77 00 302dania.dipietropaolo@asclepion.com |
| Preparation Date: | November 8th, 2019 |
| Trade Name: | MeDioStar |
| Common Name: | MeDioStar Diode Laser device |
{5}------------------------------------------------
Image /page/5/Picture/0 description: The image shows the logo for Asclepion Laser Technologies. The logo features the word "Asclepion" in a bold, gray font, with the "i" in "Asclepion" colored in a dark blue. Below "Asclepion" is the phrase "Laser Technologies" in a smaller, gray font. Above and to the right of the word "Asclepion" are several dark blue circles of varying sizes, arranged in a semi-circular pattern.
| Classification Name: | Laser surgical instrument for use in general and plastic surgery and indermatology79-GEX21 CFR 878.4810Regulatory Class: Class IIProduct Code: GEX |
|---|---|
| Main predicate device: | The MeDioStar NeXT Family (K143519) |
| Reference predicate devices | Primelase Excellence (K191321)LightSheer Infinity /Duet/ and Desire (K170179) |
| Device Description: | The MeDioStar is a pulsed diode laser emitting a wavelength of 750 - 950 nmthat is operated with a handpiece in contact with the skin. The systemcomprises a main console unit, a handpiece and is triggered by means of afootswitch. There are several handpieces, the user can choose from.Moreover, a specific software controls the device functions and allows theuser selections through the touchscreen display. |
| Description of the modifications: | The laser is a modification to previously cleared MeDioStar NeXT FamilyK143519 due to some technical modifications. |
| Intended Use: | The MeDioStar laser system is intended for surgical, aesthetic and cosmeticapplications in the medical specialties of general and plastic surgery anddermatology.The MeDioStar laser system is intended for the treatment of benign vascularlesions.The MeDioStar laser system is intended for the treatment of benignpigmented lesions.The MeDioStar laser system is intended for hair removal, permanent hairreduction defined as reduced hair growth with or without maintenancewhen measured at 6, 9 and 12 months. |
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image shows the logo for Asclepion Laser Technologies. The logo features the word "Asclepion" in a bold, gray sans-serif font, with the words "Laser Technologies" in a smaller, lighter gray font underneath. To the right of the word "Asclepion" is a cluster of blue circles of varying sizes, arranged in a pattern that suggests a network or constellation.
Description of the modifications:
This Special 510(k) of MeDioStar is submitted due to Device Modifications of the already cleared device The MeDioStar NeXT Family (K143519) due to some technical modifications. The same technological characteristics (material, components, energy source) as the predicate device except for the differences shown in the table below.
| The MeDioStar NeXT Family | LightSheer Infinity /Duet/and Desire | PrimelaseExcellence | Subject Device | |
|---|---|---|---|---|
| software | - | - | - | GUI Design changed |
| Handpiece Port | Single | Double | Single | Double |
| Repetition Rate | 4-12 Hz | Up to 3 Hz | Up to 10 Hz | Up to 20 Hz |
| Handpieces | - | - | - | Slightly changes in the dimension and maxFluence per handpiece |
| USB drive forpatient datatransfer | Yes | No | - | No |
The modified device has the same intended device MeDioStar NeXT Family (K143519). Moreover, the intended use of the modified device, as described in its labeling, has not changed as a result of the modifications.
The functionality of MeDioStar with two handpiece ports was tested successfully by means of software verification and validation. Furthermore, the MeDioStar laser with two handpiece ports is substantially equivalent to the Lumenis LightSheer diode laser K170179 with similar parameter and the same Indications for use.
Page 3 of 5
{7}------------------------------------------------
Compared to the predicate device MeXt Family, the maximum adjustable fluence in case of hair reduction changed slightly: this is due to the fact that the high power (HP) hand piece is not included in this submission.
Briefly, based on the nature of the changes implement and successfully passed performance testing and software verifications and validation according to the relevant standards.
A comparison of the technical characteristics of the subject device and its predicates follows:
| Subject device | Main predicate device | Reference predicatedevice | Reference predicatedevice | |
|---|---|---|---|---|
| model name | MeDioStar | MeDioStar NeXT Family | Primelase Excellence | LightSheer Infinity /Duet/and Desire |
| manufacturer | Asclepion Laser Technologies GmbH | Asclepion Laser Technologies GmbH | High TechnologyProducts SLU | Lumenis Ltd |
| 510(k) | (K192483) | K143519 | K191321 | K170179 |
| Laser Source | Diode Laser | Diode Laser | Diode Laser | Diode Laser |
| Wavelength range | 755-950 | 755-950 | 805-1060 | 805-1060 |
| Pulse duration | Up to 400 ms | Up to 400 ms | Up to 400 ms | Up to 400 ms |
| Max. Fluence (J/cm2) | 210 | 210 | 43 | 100 |
| Max. Fluence (J/cm²)Hair reduction | 60 | 90 (HP handpiece), otherwise 60 | 43 | 100 |
| Repetition Rate | Up to 20 Hz | 4 — 12 Hz | Up to 10 Hz | Up to 3 Hz |
| Intended Use | Intended for surgical, aesthetic andcosmetic applications in the medicalspecialties of general and plastic surgeryand dermatology.Intended for the treatment of benignvascular lesions.Intended for hair removal, permanenthair reduction and the treatment ofbenign pigmented lesions. | Intended for surgical, aesthetic andcosmetic applications in the medicalspecialties of general and plasticsurgery and dermatology.Intended for the treatment ofvascular lesions.Intended for hair removal, permanenthair reduction and the treatment ofpigmented lesions. | Intended for hair removaland permanent hairreduction | Intended for surgical,aesthetic and cosmeticapplications in the medicalspecialties of general andplastic surgery anddermatology.Intended for thetreatment of benignvascular lesions.Intended for hair removal,permanent hair reductionand the treatment ofbenign pigmented lesions. |
| Handpiece Port | Double | Single | Single | Double |
{8}------------------------------------------------
Image /page/8/Picture/0 description: The image shows the logo for Asclepion Laser Technologies. The word "Asclepion" is written in a gray, sans-serif font. Below that, the words "Laser Technologies" are written in a smaller, gray, sans-serif font. To the right of the word "Asclepion" is a cluster of blue circles of varying sizes.
The MeDioStar laser system is substantially equivalent to the Comparison to: MeDioStar NeXT Family K143519 with the same principles of operation, with similar parameter and the same indications for use. The fundamental scientific technology of the device is unchanged from the legally marketed predicate. The MeDioStar laser with two handpiece ports is substantially equivalent to the Lumenis LightSheer diode laser K170179 with similar parameter and the same Indications for use.
Non clinical Performance Data:
The following performance data were applied in support of the substantial equivalence determination:
- ISO 60601-1: Medical electrical equipment Part 1: General requirements for safety and essential ● performance
- ISO 60601-1-2 Medical electrical equipment - Part 1-2: General requirements for safety and essential performance - Collateral standard: Electromagnetic compatibility - Requirements and tests
- IEC 62304:2006+A1:2015 Medical Device Software - Software life cycle processes
- IEC 62366-1 Medical devices Application of usability engineering to medical devices ●
- IEC 60601-2-22 Ed.3.1 Medical electrical equipment Part 2: Particular requirements for the safety ● of diagnostic and therapeutic laser equipment
- ISO 14971 2nd Ed. Medical devices - Application of risk management to medical devices
- Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices".
MeDioStar passed all the required testing and is in compliance will all applicable sections of the abovementioned performance standards.
Biocompatibility:
The biocompatibility of MeDioStar is established based on the predicate devices.
Clinical Performance Data: None
Comparison with predicate device
The subject device and predicate device MeDioStar NeXT Family have the same intended use and the same fundamental scientific technology, based on diode laser sources.
Summary
The device MeDioStar is substantially equivalent to its identified predicate device MeDioStar NeXT Family (K143519).
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.